Marco Distefano

Marco Distefano

Auto-generated profile, based on publicly available information

Marco Distefano

Department of Digestive Diseases, Campus Bio Medico University of Rome, Roma, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 December 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
RLRomain Lévy
Romain Lévy
FGFlorian Gothe
Florian Gothe
MMMana Momenilandi
Mana Momenilandi
TMThomas Magg
Thomas Magg
MMMarie Materna
Marie Materna
VZVictorya Zakharova
Victorya Zakharova
Patients with inherited CARMIL2 or CD28 deficiency have defective T cell CD28 signaling, but their immunological and clinical phenotypes remain largely unknown. We show that only one of three CARMIL2 isoforms is produced and functional across leukocyte subsets. Tested mutant CARMIL2 alleles from 89 patients and 52 families impair canonical NF-κB but not AP-1 and NFAT activation in T cells stimulated via CD28. Like CD28-deficient patients, CARMIL2-deficient patients display recalcitrant warts and low blood counts of CD4+ and CD8+ memory T cells and CD4+ TREGs. Unlike CD28-deficient patients, they have low counts of NK cells and memory B cells, and their antibody responses are weak. CARMIL2 deficiency is fully penetrant by the age of 10 yr and is characterized by numerous infections, EBV+ smooth muscle tumors, and mucocutaneous inflammation, including inflammatory bowel disease. Patients with somatic reversions of a mutant allele in CD4+ T cells have milder phenotypes. Our study suggests that CARMIL2 governs immunological pathways beyond CD28.

24 June 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
MRMentore Ribolsi
Mentore Ribolsi
LMLorenzo Marchetti
Lorenzo Marchetti
CCChiara Catamo
Chiara Catamo
LGLaura Galdi
Laura Galdi
MDMarco Distefano
Marco Distefano
Michele CicalaMichele Cicala
Michele Cicala
Background: Acid exposure time (AET) is the reference metric quantifying esophageal acid burden, yet patients with pathological AET may fail to respond to PPI therapy. Given the logarithmic nature of pH, AET does not account for the exponential increase in hydrogen ion (H + ) concentration at lower pH values. Aim: To quantify acid burden using total integrated acidity exposure (TIAE), a dose-based metric integrating H + load over time, and to assess whether TIAE improves prediction of PPI response compared with conventional AET. Methods: Impedance-pH data were retrospectively evaluated. TIAE was calculated by integrating H + concentration (10 -pH ) at 1-second resolution across all acid reflux episodes. Diagnostic performance for PPI response was assessed using ROC analysis, multivariable logistic regression and decision curve analysis (DCA). Results: Among 174 patients (97 PPI responders, 77 non-responders), responders exhibited higher TIAE than non-responders and controls (p<0.0001). TIAE showed superior discrimination for PPI response compared with AET (AUC 0.78 vs 0.64). In multivariable models, TIAE independently predicted response both as a dichotomized and continuous variable, whereas continuous AET was not independently associated. TIAE correlated more strongly with MNBI than AET (ρ=-0.49 vs -0.26). DCA demonstrated greater net clinical benefit for models incorporating TIAE across clinically relevant threshold probabilities. In patients with inconclusive AET (4-6%), TIAE accurately segregated responders from non-responders. Very low pH (pH<2) greatly affected TIAE value and showed the strongest association with treatment response. Conclusions: Quantifying H + load provides a physiologically grounded assessment of esophageal acid burden and improves prediction of PPI response.